Language  ||  English : Spanish : Arabic  
Home Company Profile Business Opportunity QualityControl Manufacturing Contact Us
.
 
 
Products
  
  INJECTIONS
 
 
  ORALS
 
 
OLDER PACKAGING
 
 
 
test-plex 300 testosterone
Click to enlarge
 

Test-Plex 300

 
COMPOSITION
Each ml contains:
Testosterone Acetate 30 mg
Testosterone Propionate USP 30 mg
Testosterone Phenylpropionate 60 mg
Testosterone Isocaproate 60 mg
Testosterone Cypionate USP 60 mg
Testosterone Enanthate USP 60 mg
Oil Base q.s.
 
CHEMICAL INFORMATION
Chemical: 17β-Hydroxyandrost-4-en-3-one
Molecular Formula: C19H28O2
Molecular Weight 288.4244 g/mol
 
 
COA
 
Chem Structure
DESCRIPTION
Test-Plex 300 is an oil based solution of six testosterone esters for IM injection including those of short, intermediate, and long half-lives. Serum testosterone will rapidly increase within 24 hours of IM administration and remain elevated for 7 - 10 days. Test-Plex 300 is suitable for the treatment of hypogonadism and other disorders related to androgen deficiency. Test-Plex 300 has both anabolic and androgenic effects. Testosterone supplementation has been demonstrated to increase strength and growth of new muscle tissue, frequently with increases in libido.
INDICATIONS
Adult Males: Test-Plex 300 Injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.
Primary hypogonadism: Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy.
Hypogonadotropic hypogonadism: Idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
CLINICAL PHARMACOLOGY
Testosterone and dihydrotestosterone are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution and have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.
Male hypogonadism results from insufficient secretion of testosterone and is characterized by low serum testosterone concentrations. Symptoms associated with male hypogonadism include decreased sexual desire with or without impotence, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics, and osteoporosis. Hypogonadism is a risk factor for osteoporosis in men. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.
During exogenous administration of androgens, endogenous testosterone release may be inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
Esterification of testosterone at position 17 increases the lipid solubility of the testosterone molecule and prolongs the activity of the molecule by increasing its residence time. Following intramuscular administration in an oily vehicle, testosterone ester is slowly absorbed into the circulation and rapidly hydrolysed in plasma to testosterone.
In a study of healthy males, a single injection of 200 mg of testosterone cypionate increased mean serum testosterone concentrations sharply to 3 times the basal levels (approximately 1350 ng/dl) at 24 hours and declined gradually to basal levels (approximately 500 ng/dl) by day 10.
Circulating testosterone is chiefly bound in the serum to sex hormone-binding globulin (SHBG) and albumin. Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are estradiol and dihydrotestosterone.
ADVERSE REACTIONS
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.
CONTRAINDICATIONS
Patients with known hypersensitivity to any ingredients in this product.
Patients with known or suspected carcinomas of the breast, testis, or prostate.
Patients with severe heart disease, liver disease, or kidney disease or with a history of epilepsy.
Products containing testosterone should not be used in women as they may cause virilization and fetal harm.
PRECAUTIONS
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease.
Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs.
PATIENT MONITORING
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult Male: 150 - 300mg injected IM every 1 to 2 weeks or as directed by physician.
PRESENTATION
Test-Plex 300 (300mg/ml) in 10ml multiple dose vial OR 10 ampules of 1ml each.
STORAGE
Protect from light. Store at 15 - 25oC.
 
 
  PRODUCT AUTHENTICATION : NEWS / EVENTS  
 
 
 
 
 
 
  Magnum Pharmaceuticals Authentication

Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.

Android OS | Blackberry OS | iOS | Windows Phone OS

 
 
 
TERMS & CONDITIONS   PAYMENT   SHIPPING
2012 © All Rights Reserved Magnum Pharmaceuticals Co., Ltd.

Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.

Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.